Tarsus Pharmaceuticals, Inc. to Present at the BofA Securities 2021 Virtual Health Care Conference
April 27 2021 - 4:05PM
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage
biopharmaceutical company whose mission is to focus on unmet needs
and apply proven science and new technology to revolutionize
treatment for patients, starting with eye care, today announced
Bobak Azamian, M.D., Ph.D., President and Chief Executive Officer
of Tarsus, will present an overview of the company at the BofA
Securities 2021 Virtual Health Care Conference. In addition to the
presentation, the management team will host investor meetings at
the conference.
Presentation DetailsDate: Wednesday, May 12Time: 5:00 PM ET/
2:00 PM PTWebcast:
https://www.veracast.com/webcasts/bofa/hc2021/id5V4C40.cfm
The live webcast will be hosted on ir.tarsusrx.com and
available for replay for a period of 90 days.
About Tarsus Pharmaceuticals,
Inc.Tarsus Pharmaceuticals, Inc. is a late clinical-stage
biopharmaceutical company that applies proven science and new
technology to revolutionize treatment for patients, starting with
eye care. It is advancing its pipeline to address several diseases
with high unmet need across a range of therapeutic categories,
including eye care, dermatology, and infectious disease prevention.
Its lead product candidate, TP-03, is a novel therapeutic in a
pivotal Phase 2b/3 trial for the treatment of Demodex blepharitis.
TP-03 is also being developed for the treatment of Meibomian Gland
Disease.
Forward-Looking
StatementsStatements in this press release about future
expectations, plans and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
“forward-looking statements.” These statements include statements
regarding the market size for TP-03, future events and Tarsus’
plans for and the anticipated benefits of its product candidates
including TP-03, the timing, objectives and results of the clinical
studies and anticipated regulatory and development milestones and
the quotations of Tarsus’ management. The words, without
limitation, “believe,” “contemplate,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “might,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “will” or
“would” or the negative of these terms or other similar expressions
are intended to identify forward-looking statements, although not
all forward-looking statements contain these or similar identifying
words. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors. Important factors that could cause actual results to
differ materially from those in the forward-looking statements
include: Tarsus has incurred significant losses and negative cash
flows from operations since inception and anticipates that it will
continue to incur significant expenses and losses for the
foreseeable future; Tarsus may need to obtain additional funding to
complete the development and any commercialization of its product
candidates, if approved; Tarsus is heavily dependent on the success
of its lead product candidate, TP-03 for the treatment of Demodex
blepharitis; the COVID-19 pandemic may affect Tarsus’ ability to
initiate and complete preclinical studies and clinical trials,
disrupt regulatory activities, disrupt manufacturing and supply
chain or have other adverse effects on Tarsus’ business and
operations; even if TP-03 or any other product candidate that
Tarsus develops receives marketing approval, Tarsus may not be
successful in educating eye care physician and the market about the
need for treatments specifically for Demodex blepharitis and or
other diseases or conditions targeted by Tarsus’ products; the
development and commercialization of Tarsus products is dependent
on intellectual property it licenses from Elanco Tiergesundheit AG;
Tarsus will need to develop and expand the company and Tarsus may
encounter difficulties in managing its growth, which could disrupt
its operations; the sizes of the market opportunity for Tarsus’
product candidates, particularly TP-03 for the treatment of Demodex
blepharitis and MGD, have not been established with precision and
may be smaller than estimated; the results of Tarsus’ earlier
studies and trials may not be predictive of future results; any
termination or suspension of, or delays in the commencement or
completion of, Tarsus’ planned clinical trials could result in
increased costs, delay or limit its ability to generate revenue and
adversely affect its commercial prospects; and if Tarsus is unable
to obtain and maintain sufficient intellectual property protection
for its product candidates, or if the scope of the intellectual
property protection is not sufficiently broad, Tarsus’ competitors
could develop and commercialize products similar or identical
Tarsus’ product. Further, there are other risks and uncertainties
that could cause actual results to differ from those set forth in
the forward-looking statement and they are detailed from time to
time in the reports Tarsus files with the Securities and Exchange
Commission, including Tarsus’ Form 10-K for the year ended December
31, 2020 filed with the SEC on March 31, 2021, which Tarsus
incorporates by reference into this press release, copies of which
are posted on its website and are available from Tarsus without
charge. However, new risk factors and uncertainties may emerge from
time to time, and it is not possible to predict all risk factors
and uncertainties. Accordingly, readers are cautioned not to place
undue reliance on these forward-looking statements. Any
forward-looking statements contained in this press release are
based on the current expectations of Tarsus’ management team and
speak only as of the date hereof, and Tarsus specifically disclaims
any obligation to update any forward-looking statement, whether as
a result of new information, future events or otherwise.
Media Contact: SuJin Oh Shop PR (917) 841-5213
sujin@shop-pr.com Investor Contact: Patti
Bank Westwicke Partners, an ICR company (415) 513-1284
IR@tarsusrx.com
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From Sep 2023 to Sep 2024